Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein

ABSTRACT

Glycoprotein (GPIR) having the ribosome-inhibiting activity of the native GPIR and having a prolonged-action in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous reduction with cyanoborohydride ions. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin having a prolonged-action in vivo.

The present invention relates to new medicinal molecules containing atleast one antibody covalently bonded to a constituent of polypeptidetype which inhibits protein synthesis and is derived from a glycoprotein(or a glycopeptide) whose polysaccharide units have been modified.

U.S. Pat. No. 4,340,535 and French Patent Application Nos. 2 504 010 and2 516 794 describe the preparation of anticancer products, calledconjugates, which are obtained by the coupling, by means of a covalentbond, of the A chain of ricin with antibodies or antibody fragmentsdirected against antigens carried by the cell to be destroyed. Theproducts of this type have been designated, and are designated in thepresent Application, by the generic name of immunotoxins.

Conjugates analogous to the previously described immunotoxins containingthe A chain of ricin are known which are also suitable as anticancerdrugs and result from the coupling, by means of a covalent bond, ofantibodies or antibody fragments with other glycoproteins whichinactivate ribosomes, such as, in particular, the gelonine extractedfrom Gelonium multiflorum (Eur. J. Biochem. 1981, 116, 447-454: CancerRes. 1984, 44, 129-133 or the inhibitor extracted from Momordicacharantia (MOM) (U.S. Pat. No. 4,368,149).

These glycoproteins which inactivate ribosomes (abbreviated to GPIR),and which have properties similar to those of the A chain of ricin, aresubstances with a molecular weight of the order of magnitude of 20,000and 30,000 (Cancer Survey, 1982, 1, 489-520).

The term "glycoprotein which inactivates ribosomes", as used in thepresent description and also in the claims, denotes any substance whichcarries saccharide units belonging to the class of macromolecules whichinactivate ribosomes and consequently inhibit protein synthesis ineucaryotic cells, as well as any fragment of the said substance whichpossesses the same inactivating property, it being possible for the saidglycoprotein which inactivates ribosomes to be of natural orbiosynthetic origin, being derived from a cell whose genotype has beenmodified for this purpose.

It is also known that the cytotoxic activity of these immunotoxins canbe potentiated by a variety of adjuvant substances such as ammoniumsalts, various amines or certain carboxylic ionophores such as monensinor nigericin.

However, the therapeutic effects of immunotoxins, whether activated ornot, can only manifest themselves fully on condition that theimmunotoxin is capable, through its antibody part, of becoming localizedin vivo, in the active form, on the target cells to be destroyed (sinequa non condition for any expression of immunotoxin activity). Thecapacity of the immunotoxin to become localized on the target dependsfirst and foremost on the ability of the immunotoxin to remain in thebloodstream and the extracellular fluids, in the active form, forsufficient lengths of time for it to reach its target cells and atsufficient concentrations to give a high degree of occupation of thecorresponding antigen sites.

Numerous studies have made it possible to establish the plasmaelimination kinetics of immuno-toxins after intravenous injection intovarious animal models. It has been found that, after injection, theplasma level of biologically active immunotoxin decreases very rapidlyand very substantially. Thus, in a typical case involving rabbits, in amodel using an immunotoxin built up by coupling the A chain of ricin, bymeans of a link containing a disulfide bridge, with a monoclonalantibody directed against the antigen T65 of human T lymphocytes(antibody TlOl), it is found that 97% of the immunotoxin present in thebloodstream at time 0 after injection disappears in 30 minutes and 99.9%disappears in 17 hours. This rapid disappearance of the immunotoxinquite obviously detracts from the expression of its complete cytotoxiccapacity, the immunotoxin being prevented from durably saturating a highproportion of the target antigens carried by the cells to be destroyed.Moreover, a comparison of the plasma elimination kinetics ofimmunotoxins with those of the corresponding unconjugated antibodiesshows by contrast that--as is well known--the antibodies remain in theplasma at a high level for relatively long periods of time. Now, even inthe most highly purified immunotoxin preparations, there is always acertain residual level of unconjugated antibodies. Due to the effect ofthe differential rates of elimination of immunotoxins and antibodies,the unconjugated antibodies, which are initially very much in theminority, progressively become the majority component after a few hours,so these antibodies gradually compete to become powerful antagonists forthe fixation of the immunotoxins to their targets.

Therefore, this clearly shows the value of enhancing the persistence ofimmunotoxins in the plasma, in their active form, so as to increase boththe duration and degree of occupation of the target antigens andconsequently to improve.the therapeutic effects of the immunotoxins.

Furthermore, experiments involving in vivo localization of theimmunotoxin containing the A chain of ricin, radiolabeled and theninjected into animals with no specific target, have shown that theconjugate becomes localized preferentially in the liver during the firstfew minutes after injection. The same applies to the A chain of ricin,which follows the same pattern when injected in the uncoupled form. Thisstrongly suggests that the immunotoxin becomes fixed in the liver viathe cytotoxic sub-unit contained in the immunotoxin.

It is known that the A chain of ricin is a glycoprotein whose polyosidicgroups comprise especially mannose residues and N-acetylglucosamineresidues, some mannose residues being in terminal positions (Agri. Biol.Chem., 1978, 42, 501). Also, receptors capable of recognizingglycoproteins containing these terminal mannose residues have been foundto exist in the liver. It has also been shown that the glycoproteinsrecognized by these receptors--the latter being present essentially onthe Kupffer cells--are rapidly eliminated from the bloodstream byfixation to these cells, which metabolize them. This is well documentedespecially in the case of beta-glucuronidase and in the case ofribonuclease B (Arch. Biochem. Biophys., 1978, 188, 418; Advances inEnzymology, published by A. Meister, New York, 1974; Pediat. Res., 1977,11, 816).

Taken as a whole, this information shows that the rapid elimination ofimmunotoxins containing the A chain of ricin can be explained by therecognition of the mannose residues of the A chain of ricin by thehepatic cells and in particular the Kupffer cells.

The studies of plasma elimination kinetics carried out on other GPIRs.for example gelonine or MOM, after intravenous injection into theanimal, have shown that, as in the case of the A chain of ricin, theplasma level of GPIR decreases very rapidly and very substantially afterinjection. Thus, in a typical case involving rabbits, after theinjection of gelonine purified by the method described (J. Biol. Chem.,1980, 255, 6947-6953), it is found that 93% of the gelonine present inthe bloodstream at time 0 after injection disappears in 1 hour and99.99% disappears in 24 hours.

It is known that the oxidation of osidic structures, including thosecontained in glycoproteins, with periodate ions causes the scission ofthe carbon chain wherever two adjacent carbon atoms carry primary orsecondary hydroxyls. If the two adjacent hydroxyls are secondary, as isgenerally the case in the cyclic oses present in GPIRs, oxidationproduces two aldehyde groups on the carbons between which the scissionhas taken place.

It is also known that aldehyde functions are very reactive towardsprimary amine groups with formation of imines also known as Schiff'sbases. Thus, the aldehyde groups formed during the oxidation reactioncan react with primary amines carried by the peptide chain ofglycoprotein and form undesirable intra- and/or intermolecular covalentbonds, leading to an instability of the oxidation product and often inthe formation of insoluble polymers.

It is also known that the formation of Schiff's bases can be preventedif the aldehyde groups created by the periodate oxidation are quicklyreduced into stable primary alcohol. Such reduction can be carried outwith reducing agents such as borohydride ions. The cyanoborohydride ionis a particularly suitable reagent since the periodate ion and thecyanoborohydride ion can co-exist without the reducing agent making theperiodate ion lose its oxidizing power, and vice versa.

It has now been found, absolutely unexpectedly, that, if thecarbohydrate units of a GPIR are modified by the original processdescribed hereinafter, a new molecule of GPIR is obtained which has thedual property of retaining its biological activities and of beingeliminated very slowly from the blood stream after injection in superioranimals or in humans. Said new modified GPIR which has retained theproperty of inactivating ribosomes and which has acquired because of themodification, a prolonged action in vivo, is denoted in the presentapplication by the symbol GPIR-1a.

This original process consists in modifying the osidic units of the GPIRby simultaneous reaction with periodate ions and cyanoborohydride ions.Thus, the aldehyde groups created by the oxidation with periodate arereduced as and when they appear, into stable primary alcohol groups, bythe cyanoborohydride ions, thus preventing the undesirable reactionswith the amino groups of the GPIR and permitting the obtention of astable and very soluble product.

It has also been found that, if this new molecule of prolonged-actionGPIR is coupled with antibody or antibody fragments, the resultingconjugates retain the known biological properties of immunotoxins andexhibit slow plasma elimination kinetics.

The present invention therefore relates, as new product, to astructure-modified GPIR, whose carbohydrate units have been modified bythe joint action of periodate ions and of cyanoborohydride ions, thelatter reducing into stable primary alcohol groups the aldehyde groupscreated by the oxidation with periodate, as and when these groupsappear. The present invention further relates to the method forpreparing the GPIR modified as described hereinabove.

The present invention also relates to products belonging to the class ofthe immunotoxins, which are obtained by covalent coupling between, onthe one hand, an antibody or antibody fragment, used in its natural formor correctly modified, and on the other hand, a molecule of GPIR whosecarbohydrate units have been modified as described hereinabove.

The meaning is given hereunder of the different products used incarrying out the invention.

The term "periodate" denotes the IO₄ ⁻ present in aqueous solutions ofperiodic acid salts and in particular salts deriving from alkalinemetals. Said salts are also mentioned in the literature under the nameof metaperiodates.

The term "cyanoborohydride" designates the CNBH⁻ ion present in aqueoussolutions of cyanoborohydrides and in particular those derived fromalkali metals.

The term "antibody" denotes a protein selected from any antibody orantibody fragment, or any immunoglobulin or immunoglobulin fragment orany molecule derived from the above by artificial modification of anyone of their functional groups, including osidic structures that theycarry, with the proviso that the protein chosen in this way remainscapable of selectively recognizing a given antigen on the surface of thecells carrying this antigen, and in particular cancerous cells. Thestarting antibody may be polyclonal or monoclonal. The starting proteinmay be of natural or biosynthetic origin, being derived from a cellwhose genotyps has been modified for this purpose.

The preparation of monoclonal antibodies directed in particular againstdefinite human target cells has been widely covered in the scientificliterature and many of these antibodies are now available on the market.

The symbol P represents a protein chosen from the group comprising anyantibody or antibody fragment, any immunoglobulin or immunoglobulinfragment or any molecule derived from the above by artificialmodification of any one of their functional groups, includingcarbohydrate structures which they carry, with the proviso that theprotein chosen in this way remains capable of selectively recognizing agiven antigen on the surface of the cells carrying this antigen,especially the target cells. The starting protein P can be of natural orbiosynthetic origin, being derived from a cell whose genotype has beenmodified for this purpose.

The symbol "GPIR" represents a glycoprotein which inactivates ribosomesor one of its fragments: provided that such fragments retain all or partof the ribosomes inactivating property which characterizes the GPIR fromwhich they are issued, they can also be used as starting products, butthe native GPIR is preferred.

The symbol "GPIR-1a" represents the GPIR modified according to theinvention, namely a molecule having the property of inactivatingribosomes like the GPIR but having a period of action in vivo which isgreater than that of the GPIR and which results from the treatment ofthe GPIR jointly with an aqueous solution of an oxidizing agent such asa periodate and an aqueous solution of a cyanoborohydride. The operationis generally conducted at a pH of between 5 and 7 in the absence oflight and for a period of 0.2 to 24 hours.

In the immunotoxin, the GPIR-1a part is also denoted as a "cytotoxicsub-unit".

The symbol A-1a represents a prolonged-action glycoprotein whichinactivates ribosomes, obtained by treatment of the A chain of ricin, inwhich at least one of the thiol groups of its cysteines 171 and 257 isoptionally protected, with an aqueous solution of an alkali metalperiodate and a cyanoborohydride. for a period of 0.2 to 24 hours at atemperature of 0° to 15° C. and in the absence of light, and bydeprotection of the said thiol group, if appropriate.

The symbol P' represents a radical derived from the above protein p, assuch or appropriately chemically modified, from which one or more of itsown groups have been removed and in which other functional groups areoptionally blocked.

The symbol GPIR-1a' represents a radical derived from the above proteinGPIR-1a, as such or appropriately chemically modified, from which one ormore of its own groups have been removed and in which other functionalgroups are optionally blocked.

The symbol A-1a' represents a radical derived from the protein A-1a,from which at least one of the thiol groups of its cysteines 171 and 257have been removed.

The symbol P₁ represents one of the proteins GPIR-1a and P as definedabove, which carries free thiol groups attached to the said proteindirectly or via a spacing structure.

The symbol P₂, which is different from P₁, represents one of theproteins GPIR-1a and P as defined above, which carries one or morefunctional groups capable of reacting with the free thiols.

The symbol P₁, represents that radical of the protein P₁ which is bondedto the groups belonging to the protein P₁, especially the groups SH (ofthe cysteine), NH₂ (in the terminal position of the protein or in theepsilon position of the lysines), OH (of the tyrosines) or COOH (of theaspartic and glutamic acids), or, only in the case where P₁ is anantibody or antibody fragment, that radical of the protein P₁ whichoriginates from the opening of the carbohydrate structures by reactionwith periodic acid according to known methods.

The symbol P_(2') represents that radical of the protein P₂ which isbonded to the characteristic functional groups NH₂ (in the terminalposition of the protein or in the epsilon position of the lysines), OH(of the tyrosines) or COOH (of the aspartic and glutamic acids).

For example, P_(1') --SH represents the protein P₁ (which canarbitrarily be the antibody or antibody fragment P or the proteinGPIR-1a) in which the SH groups of the cysteines are free and the otherfunctional groups are optionally blocked.

In the same way, P_(1') --CO-- represents the protein P₁ in which theterminal carboxyl group or the carboxyl groups of its glutamic andaspartic acids are coupled with a group which artificially introduces anSH group.

Again, P_(2') --NH-- represents the protein P₂ (which can arbitrarily bethe antibody or antibody fragment P or the protein GPIR-1a) in which theterminal amino group or the amino groups of its lysines are attached toa group capable of coupling with the thiol of the protein P₁.

The term "inert spacing structure", as used here for E and E', denotes adivalent organic radical which is inert towards the reactants used inthe process, such as a straight-chain or branched alkylene groupcontaining from 1 to 15 carbon atoms, which can contain one or moredouble bonds, can be interrupted by oxygen atoms or can be substitutedby one or more inert functional groups such as methoxy groups, free oresterified carboxyl groups, dialkylamino groups or carbamate groups. Thesame term also denotes an arylene group containing from 6 to 15 carbonatoms, which can be substituted by one or more inert functional groupsas indicated above for the alkylene group.

The expression "functional group capable of bonding covalently", as usedhere for Y and Y', denotes any groups capable of reacting with thegroups belonging to the proteins P₁ and P₂ to give a covalent bond.Thus, the groups --CO-- and --(C═NH)-- are suitable functional groupscapable of bonding with the free amines, the thiols and the phenolichydroxyls of the proteins Likewise, the --NH-- group is a suitablefunctional group capable of bonding with the free carboxyl groups of theproteins. The group ═N-- is a suitable functional group capable ofbonding with the two carbon atoms of the carbohydrate structures of theproteins P₁ and P₂ after oxidation with periodate ions, but only in thecase where P₁ and P₂ are an antibody or an antibody fragment.

The expression "group belonging to the proteins", as used here for Z andZ', denotes the radicals originating from the characteristic groups ofthe amino acids forming the proteins P₁ and P₂, such as the oxygen atomoriginating from the hydroxyls of the tyrosine and possibly serine aminoacids, the carbonyl group originating from the terminal carboxyl or thefree carboxyls of the aspartic and glutamic acids, the --NH-- grouporiginating from the terminal amine of the proteins, for example thelysine, or the sulfur atom originating from the thiol of the cysteine.The same expression also denotes the group originating from thedialdehyde structure obtained after oxidation of one of the carbohydratestructures of the proteins P₁ and P₂ by treatment with periodate ions,but only in the case where P₁ and P₂ are an antibody or antibodyfragment.

The term "activating radical", as used here for X, denotes a groupbonded to an --S--S-- bridge and capable of reacting with a free thiolto form a disulfide with the release of X--SH. Suitable activatingradicals are pyridin-2-yl and pyridin-4-yl groups which areunsubstituted or substituted by one or more halogens or alkyl, carboxylor alkoxycarbonyl radicals; the phenyl group which is unsubstituted or,preferably, substituted by one or more halogens or nitro, alkoxy,carboxyl or alkoxycarbonyl groups; or an alkoxycarbonyl group such asmethoxycarbonyl.

The terms "alkyl" and "alkoxy" denote groups containing up to 5 carbonatoms.

The term "alkylene" denotes straight-chain or branched saturatedaliphatic groups containing up to 10 carbon atoms, which can besubstituted by one or more inert functional groups such asalkoxycarbonyl groups.

The glycoproteins which inactivate ribosomes and which are used asstarting materials for oxidation with periodate, ions and reduction,according to the invention, are all GPIRs, such as the A chain of ricin,which are in themselves only very slightly cytotoxic because they cannotfix to cells, but which, on the other hand, after coupling with anantibody recognizing particular cells, become highly cytotoxic towardsthese cells once the antibody has recognized its target.

Representative starting compounds are the A chain of ricin, gelonine andthe substance extracted from Momordica charantia (MOM), as obtained byextraction.

Other GPIRs which are useful as starting materials for oxidation withperiodate ions are as follows:

    ______________________________________                                        List                                                                          ______________________________________                                        Dianthin 30      from Dianthus caryophyllus                                   Dianthin 32      from Dianthus caryophyllus                                   Agrostin A       from Agrostemma gitnago                                      Agrostin B       from Agrostemma gitnago                                      Agrostin C       from Agrostemma gitnago                                      HCI              from Hura crepitans                                          Asparagus officinalis                                                                          from Asparagus officinalis                                   inhibitor                                                                     ______________________________________                                    

The same substances produced biosynthetically by cells whose genotypehas been modified for this purpose are also suitable compounds.

Fragments of the above GPIRs, provided they retain all or part of theproperty of inactivating ribosomes which characterizes the GPIR fromwhich they are derived, can also be used as starting materials.

The native A chain of ricin in which at least one of the thiol groups isprotected is a preferred starting compound.

The preparation of the pure A chain of ricin is described in U.S. Pat.No. 4,340,535. Gelonine and MOM are also described.

Protection of the thiol groups of the starting GPIRs is only necessaryif the said thiol groups are those which are to be used for couplingwith the antibody. If other functional groups are used for the coupling,for example the phenolic hydroxyl of the tyrosines, or amino groups orcarboxylic groups of the GPIR, protection is not carried out.

Blocking is carried out by reaction with a reagent capable ofsubstituting the SH groups with a radical which can subsequently beremoved by reduction or thiol/disulfide exchange, for example2,2'-dinitro-5,5'-dithiodibenzoic acid (DTNB) or alternatively3-(pyridin-2-yldisulfanyl)propionic acid. In the absence of such atreatment, the free thiols of the A chain may disappear during theoxidation reaction, in which case they cannot be totally regenerated.The excess blocking agent is removed by dialysis or any other suitabletreatment.

The GPIR of which the thiols are blocked is then subjected to theoxidation reaction with periodate ions and to the simultaneous reductionreaction of aldehyde groups which have appeared into primary alcoholswith the cyanoborohydride ions.

The periodate oxidation reaction and the reduction reaction are carriedout at a moderately acid pH, between 5 and 7, and preferably between 6and 6.5. The periodate is mixed with the cyanoborohydride before theaddition of the GPIR. The periodate is used in excess; moreparticularly, the concentration of alkali metal periodate is alwaysgreater than the concentration of the vicinal diols capable of beingoxidized ; concentrations of 10 to 50 mM in respect of sodium periodatefor concentrations of 1 to 10 mg/ml of cytotoxic sub-unit are suitable.The concentration of the cyanoborohydride is also greater than theconcentration of the vicinal diols capable of being oxidized :concentrations of 10 to 200 mM in respect of sodium cyanoborohydride forconcentrations of 1 to 10 mg/ml of cytotoxic sub-unit are suitable. Thetreatment, carried out at a temperature of between 0° and 15° C. andpreferably between 1° and 5° C. and in the absence of light, takesbetween 0.2 and 24 hours, preferably between 4 and 20 hours.

When the reaction is over, the remaining periodate is removed by theaddition of a reagent which consumes it, such as for example an excessof ethylene glycol, or glycerol and the by-products are removed bydialysis or by any other equivalent treatment. The product obtained atthe end of the reaction is isolated by the conventional techniques.

If the thiol groups of the starting material have been blocked,unblocking is effected by the known methods, for example by reactionwith a reducing agent capable of freeing the previously blocked thiolgroup, such as 2-mercaptoethanpl, giving the new prolonged-actionglycoprotein which inactivates ribosomes, ready to be used for couplingwith an antibody to give an immunotoxin.

In the case of the A chain of ricin, the new molecule obtained in thisway (referred to by the symbol A-1a) possesses the following mainproperties:

a molecular weight which is not significantly different from that of thenative A chain. As far as it is possible to see by polyacrylamidegradient electrophoresis, this modification only produces polymers ofthe protein in a very small quantity and does not produce anydegradation products.

a proportion of free thiol groups greater than 0.7 per mol.

an immunoreactivity towards rabbit antibodies directed against the Achain of ricin which is indistinguishable from that of the native Achain.

an inhibitory activity on protein synthesis in an acellular model whichis greater than 50% of that caused by an equal quantity of native Achain.

finally, after a single-intravenous administration to rabbits at a doseof about 0.4 mg/kg of body weight, the plasma level of theprolonged-action A chain (A-1a) present in the bloodstream 24 hoursafter injection is between 100 and 300 times greater than the plasmalevel of the native A chain in the same conditions.

A GPIR prepared as described hereinabove, can be used for preparingconjugates or immunotoxins according to the heretofore known methods.

More particularly, the present invention relates to products, belongingto the class of the immunotoxins, (hereinafter named IT) which areobtained by the covalent coupling of, on the one hand, an antibody orantibody fragment, used in its natural form or correctly modified whichpossesses the capacity to selectively recognize an antigen carried bythe intended target cells, with, on the other hand, a prolonged-actionglycoprotein GPIR named GPIR-1a, obtained by the process hereinabovedisclosed, the coupling of the 2 proteins being effected either via adisulfide bond or via a thioether bond.

An immunotoxin formed by the coupling of an antibody P with aprolonged-action glycoprotein which inactivates ribosomes, GPIR-1a, canbe represented by the following statistical formula:

    P'--W--GPIR--1a'                                           (I)

in which P' represents the radical of a protein which is an antibody oran antibody fragment P, as such or appropriately chemically modified, inwhich other functional groups are optionally blocked, CPIR-1a'represents the radical of a protein which is GPIR-1a, as such orappropriately chemically modified, in which other functional groups areoptionally blocked, and W represents a divalent covalent structurecontaining a thioether group or a disulfide group in which either thesulfur atoms are those of the cysteines of P and GPIR-1a or they arebonded to the groups belonging to P and/or GPIR-1a by spacing structurescarrying a functional group bonded to the said groups belonging to Pand/or GPIR-1a.

A thioether bond between two proteins is understood as meaning a bond ofthe type: ##STR1## in which Z, Y and E are as defined below.

The present invention preferentially relates to an immunotoxin of thestatistical formula:

    P'--W'--GPIR--1a'                                          (II)

in which P' and GPIR-1a' are as defined above and W' represents acovalent structure chosen from:

(a) a group of the formula: ##STR2## (b) a group of the formula:##STR3## (c) a group of the formula:

    --Z--Y--E--S--S--(E'--Y'--Z').sub.n -- or

(d) a group of the formula:

    --(Z'--Y'--E').sub.n --S--S--E--Y--Z--.

in which:

Z and Z', identical or different, represent the groups belonging to theproteins GPIR-1a and P, chosen from the oxygen atom originating from thehydroxyl of one of the tyrosine residues, the carbonyl group originatingfrom one of the terminal carboxyls or the free carboxyls of the asparticand/or glutamic acids of GPIR-1a and P, the --NH-- group originatingfrom one of the terminal amines of GPIR-1a and P or from one of theamines in the epsilon position of one of the lysine residues, and, onlyfor Z in the covalent structures (b) and (c), the group originating fromthe dialdehyde structure obtained after oxidation of one of thecarbohydrate structures of P with periodic acid according to the knownmethods;

Y and Y' represent functional groups capable of bonding covalently withany one of the groups Z and Z' of the proteins GPIR-1a and P;

E and E' represent inert spacing structures; and

n represents zero or 1.

The immunotoxin of the present invention are represented in simplifiedform by the formulae I and II above, but it is understood that there canbe several structures --W-- or --W'-- bonded to one and the samemolecule P and/or of GPIR-1a, hence of several GPIR-1a bonded to onlyone P and vice-versa; the number of bridges depending on the couplingmethod and on the numbers of groups belonging to P and to GPIR-1a. Thusstatistical formulae I and II also represent these products and theirmixtures of formula

    P'(W'-GPIR-1a').sub.m

in which m is an integer or a mixed number, smaller or greater than 1.

For example, if an immunotoxin is formed by the coupling of the sub-unitA of native ricin with the antibody P (for example the antibody T101)via a divalent covalent structure having a disulfide group in which onesulfur is that belonging to the cysteine 257 of the prolonged-action Achain of ricin and the other is bonded to the phenolic oxygens of thetyrosines of the antibody P by an oxopropyl group, it will have thestatistical formula:

    P'(O--CO--CH.sub.2 --CH.sub.2 --S--S--A--1a').sub.t

in which t represents the number of tyrosines in the antibody (forexample the antibody T101) which are involved in the coupling.

The resulting immunotoxin thus corresponds to a product of the formulaII in which:

P' is as defined above, especially the radical of the antibody T101 fromwhich the phenolic groups of the tyrosines involved in the coupling havebeen removed;

A-1a' is the radical of the prolonged-action A chain of ricin from whichthe thiol group of its cysteine 257 has been removed; and

W' is the group(c):

    --Z--Y--E--S--S--(E'--Y'--Z').sub.n --

in which Z is the oxygen of the phenolic hydroxyls involved in thecoupling, Y is --CO--, E is the inert spacing structure --CH₂ --CH₂ --and n is zero.

Particular preference is given to the immunotoxins formed by one or morestructures containing the prolonged-action sub-unit A of ricin and asingle antibody P, which are represented by the statistical formula:

    P'(W'---A--la').sub.m                                      III

in which P', W' and A-1a' are as defined above and m represents thenumber of groups belonging to the protein P which are involved in thecoupling. The number m varies from 0.3 to 12, preferably from 0.5 to 10.

The expression "m varies from 0.3 to 12, preferably from 0.5 to 10"means that the value of m is a statistical value because the couplingdoes not take place homogeneously within the population of antibodymolecules. The number m may therefore not be an integer.

The value of m depends especially on the antibodies used and moreparticularly on their molecular weight.

Thus, if a fragment Fab or Fab' is used as the starting antibody P, thevalue of m can vary between 0.3 and about 2; if a fragment F(ab')₂ isused, m can vary between 0.5 and about 4; for an antibody of the IgGtype, the value of m will be between 0.5 and about 6; finally, for anantibody IgM, the value of m can vary between 1 and about 12.

It is preferable, however, for the degree of substitution on theantibody P to be such as to lead to a value of m which is not less than0.5 and not more than 10.

More generally, the structures I and II above represent statisticalformulae written in simplified form, as explained above.

Analogously, the formulae IV, V and IX below are also statisticalformulae--whenever n is 1--because the coupling reactants are preparedfrom populations of proteins P₁ and P₂ which all have exactly the sameproperties as those considered above for the antibody P, whether theseproteins P₁ and P₂ are themselves the antibody P or the protein GPIR-1a.

According to another feature, the present invention relates to a processfor the preparation of a prolonged-action immunotoxin having a covalentbond of the disulfide or thioether type between an antibody and aglycoprotein which inactivates ribosomes, wherein a disulfide orthioether bond is formed between an antibody and a prolonged-actionglycoprotein which inactivates ribosomes, obtained by treatment of aglycoprotein which inactivates ribosomes, the thiol groups of which areoptionally protected, with an aqueous solution of an alkali metalperiodate, in the presence of a cyanoborhydride for a period of 0.2 to24 hours, at a temperature of 0° to 15° C. and in the absence of light,and by unblocking of the thiol group, if appropriate.

According to a preferred feature, the present invention relates to aprocess for the preparation of an immunotoxin having the structure Iabove, wherein a protein P₁, which is arbitrarily either theprolonged-action glycoprotein which inactivates ribosomes, GPIR-1a, oran antibody or antibody fragment, carrying at least one free thiol groupattached to the said protein P₁ directly or via a spacing structure, isreacted, in aqueous solution and at room temperature, with a protein P₂,which is different from P₁ and is arbitrarily either theprolonged-action glycoprotein which inactivates ribosomes, GPIR-1a, oran antibody or antibody fragment, carrying a group capable of couplingwith the free thiol of the protein P₁, so as to form a thioether ordisulfide bond.

According to a particularly advantageous feature, the present inventionrelates to a process for the preparation of an immunotoxin having thestructure II, in which P', W' and GPIR-1a' are as defined above, whereina protein of the formula:

    P.sub.1' --(Z--Y--E).sub.n --SH                            (IV)

is reacted, in aqueous solution and at room temperature, with a proteinof the statistical formula:

P_(2') --Z'--Y'--E'--G (V)

in which P_(1') and P_(2') represent the radicals of the proteins P₁ andP₂ bonded to the groups belonging to the said proteins, or, only if P₁and P₂ are an antibody or antibody fraction, the radicals of theproteins P₁ and P₂ originating from the opening of the carbohydratestructures by reaction with periodic acid, Z, Z', Y, Y', E and E' are asdefined above and G represents a group: ##STR4## or a group --S--S--X,in which X is an activating group

Therefore, both P and GPIR-1a are proteins which arbitrarily have:

(1) the thiol group or groups taking part in the coupling, and

(2) one or more functional groups capable of reacting with the abovethiol groups to form a disulfide or thioether bond.

According to the present invention, the said thiol groups and functionalgroups are those of the native proteins p or GPIR-1a or alternativelyare introduced therein artificially.

Protection of the thiol groups of the starting GPIRs is only necessaryif the said thiol groups are those which are to be used for couplingwith the antibody. If other functional groups arc used for the coupling,for example the phenolic hydroxyl of the tyrosines, protection is notcarried out.

Blocking is carried out by reaction with a reagent capable ofsubstituting the SH groups with a radical which can subsequently beremoved by reduction or thiol/disulfide exchange, for example2,2'-dinitro-5,5'-dithiodibenzoic acid (DTNB) or alternatively3-(pyridin-2-yldisulfanyl)propionic acid. In the absence of such atreatment, the free thiols of the A chain may disappear during theoxidation and reduction reaction, in which case they cannot be totallyregenerated by reaction with a reducing agent such as 2-mercaptoethanol.The excess blocking agent is removed by dialysis.

The glycoprotein which inactivates ribosomes and the thiols of which areblocked is then subjected to oxidation with periodate ions and toreduction. If, on the other hand, the cytotoxic sub-unit does notcontain thiol, or alternatively if the thiol or thiols are not used forcoupling, the blocking indicated above is not carried out.

The preparation of the conjugates or immunotoxins from theprolonged-action glycoproteins which inactivate ribosomes is carried outby any process suitably chosen from the range of processes described inU.S. Pat. No. 4,340,535. If the chosen cytotoxic sub-unit naturallycontains at least one thiol making it suitable for coupling, this groupwill preferably be used by reaction with the antibody or antibodyfragment carrying an activated disulfide group. If the chosen cytotoxicsub-unit does not naturally possess a thiol group making it suitable forcoupling, at least one functional group carrying a free thiol canpreferably be introduced artificially into the said sub-unit, after theoxidation step with periodate ions and reduction, by any known processand the coupling can be continued as indicated above.

The introduction of the said functional group can take place eitherbefore the oxidation step with periodate ions, and the reduction steps,in which case it will be necessary for the thiol radical to be blockedduring the oxidation and reduction step and then unblocked after thisstep, i.e. the oxidation and reduction step.

The chemical coupling of the GPIR-1a with the antibody (or antibodyfragment) can be effected according to the process of the presentinvention by procedures which:

preserve the respective biological activities of the two components ofthe conjugate, namely the antibody and the GPIR-1a,

ensure that the process has a satisfactory reproducibility and a goodcoupling yield,

make it possible to control the value of the ratio GPIR-1a/antibody inthe conjugate obtained,

lead to a stable and water-soluble product.

Among the procedures corresponding to these characteristics, preferencemust be given to those which involve one or more thiol groups in formingthe bond between the 2 proteins. In fact, these thiol groups areparticularly suitable for forming either disulfide bonds or thioetherbonds, both of which satisfy the general conditions above.

The preparation of immunotoxins simultaneously having the followingcharacteristics:

the covalent bond between the A chain of ricin and the antibody containsa disulfide radical,

one of the sulfur atoms forming the disulfide bond is always the sulfuratom belonging to the cysteine residue in the 257-position of the Achain of ricin, and

the link joining the A chain of ricin to the antibody is fixed to thelatter at NH₂ side groups or end groups of a peptide chain

The coupling of an antibody with the A chain of ricin is described indetail in U.S. Pat. No. 4,340,535.

The same method can be applied to the preparation of immunotoxins havingthe same characteristics and formed by the coupling of an antibody orantibody fragment with a GPIR-1a.

The preparation of immunotoxins formed by the coupling of an antibody orantibody fragment with a GPIR-1a and by a covalent bond of the disulfideor thioether type at different functional groups is described in detailbelow.

In general, in order to carry out the coupling reactions betweenproteins successfully and to eliminate disordered crosslinkings inparticular, it is important for one of the proteins to be coupled, andone only, to carry the thiol or thiol groups to be used, while the otherprotein only carries one or more groups capable of reacting with thethiols in an aqueous medium having a pH of between 5 and 9, and at atemperature not exceeding 30° C., to produce a stable and clearlydefined covalent bond.

The characteristics of the proteins P₁ and P₂ used as starting materialsare illustrated in detail below. The spacing structure E can be replacedwith the preferred structures R to R₈, which are only given as examples.

I--THE PROTEIN P₁

As this protein is in all cases the one carrying the thiol group orgroups which will take part in the coupling, the situation which arisesvaries according to the nature of this protein P₁.

(A) In the natural state, the protein P₁ carries one or more thiolradicals which can be used to permit coupling with the protein P₂ ; thisis particularly the case if the protein P₁ is the antibody fragmentknown as F(ab)', as conventionally obtained by limited proteolysis ofthe antibody in the presence of pepsin, followed by reduction of thedisulfide bridge (or bridges) between high-molecular chains.

This is also the case if the protein P₁ is a GPIR-1a, for example themodified A chain of ricin (A-1a), or a derivative thereof, in which atleast one of the thiol groups carried by the cysteine 171 and 257residues of the native A chain of ricin is free and accessible forchemical coupling.

In all these cases, the protein P₁ carrying its natural thiol group (orgroups) can be used in this state for the coupling step.

(B) In the natural state, the protein P₁ does not carry thiol radicalswhich can be used to permit coupling with the protein P₂ :

this is especially the case if the protein P₁ is a nativeimmunoglobulin, a whole antibody or an antibody fragment, especially oneof the fragments conventionally called F(ab)'₂ or F(ab);

another case in which the protein P₁ does not carry, in the naturalstate, a thiol group which can be used for coupling is the case wherethis protein P₁ is a GPIR-1a, for example the prolonged-action A chainof ricin, in which each of the two cysteine residues is either blockedby alkylation or inaccessible for chemical modification.

In all cases, it will thus be appropriate artificially to introduce intosuch molecules one or more thiol groups capable of permitting coupling.

Three types of reaction can preferably be used for the introduction ofthiol groups:

1--The first type of reaction is with S-acetylmercaptosuccinicanhydride, which is capable of acylating amino groups of the protein. Itwill then be possible to free the thiol groups by reaction withhydroxylamine to remove the acetyl protecting radical, in the manneralready described Archives of Biocbemistry and Biophysics, 119, 41-49,1967). It will even be possible, in the case where the thiol group (orgroups) thus introduced in the protected form are subsequently to reactwith an activated mixed disulfide radical, to dispense with the priordeprotection by means of hydroxylamine; in fact, the reaction creatingthe disulfide bond using the reactants forming the subject of thepresent invention takes place just as well with the S-acetyl radical aswith the free thiol.

Other methods described in the scientific literature can also be used tointroduce thiol groups into the protein to be modified.

2--The second type of reaction consists in reacting the protein via itscarboxyl groups with a symmetrical diamino molecule having a disulfidebridge, of the formula:

    H.sub.2 N--R.sub.1 --S--S--R.sub.1 --NH.sub.2

in which R₁ is an aliphatic group containing from 2 to 5 carbon atoms.

The reaction is preferably carried out with cystamine [R₁ =--(CH₂)₂ --]in the presence of a coupling agent such as a carbodiimide andespecially a water-soluble derivative like1-ethyl-3-dimethylaminopropyl-3-carbodiimide, and leads to theformation, depending on the stoichiometries used, of one of thefollowing derivatives or a mixture of both:

    P.sub.1' --CO--NH--R.sub.1 --S--S--R.sub.1 --NH.sub.2      (Ia)

    P.sub.1' --CO--NH--R.sub.1 --S--S--R.sub.1 --NH--CO--P.sub.1 '(Ib).

A reaction product of this type can then be used in two ways:

(a) If, in the formulae Ia or Ib, the protein P₁ is a GPIR-1a, forexample the prolongedraction A chain of ricin or one of its derivatives,the reaction medium obtained is subjected, without fractionation, to theaction of a reducing agent such as 2-mercaptoethanol, giving a singleprotein derivative of the general formula:

    P.sub.1' --CONH--R.sub.1 --SH.

The product thus obtained is then purified by dialysis or gelfiltration.

(b) If, in the formulae Ia and Ib, the protein P₁ is an antibody or oneof its fragments, the reaction medium obtained will be used as such forthe coupling, in which case a thiol/disulfide exchange method will beused, for example the one described by Gilliland and Collier (CancerResearch, 40, 3564, 1980).

3--The third type of reaction consists in using carbohydrate units,which are present in the natural state in the antibodies, in order tofix the radical carrying the thiol which it is proposed to introduce.The protein P₁ is then subjected to oxidation with periodate ions by theknown methods in order to create aldehyde groups on the carbohydrateunits. After the reaction has been stopped by the addition of excessethylene glycol and the by-products and excess reactants have beenremoved by dialysis, the product obtained is treated with a symmetricaldiamino molecule having a disulfide bridge, of the general formula:

    H.sub.2 N--R.sub.1 --S--S--R.sub.1 --NH.sub.2

in which R₁ is an aliphatic group containing from 2 to 5 carbon atoms.The formed addition products are then reduced in secondary or tertiaryamines by the action of a suitable metal hydride, notabIy the sodiumborohydride. The reaction is preferably carried out with cystamine [R₁=--(CH₂)₂ --] and leads to the formation, depending on thestoichiometries used, of one of the following derivatives or a mixtureof both: ##STR5##

The reaction medium obtained may then be treated exactly as indicatedabove for the products characterized by the structures Ia or Ib.

In the last two types of reaction, described above, for the artificialintroduction of thiol groups (the types using a symmetrical diaminodisulfide reactant), the protein P₁ used preferably possesses neitherfree SH groups nor free amino groups.

In the case of the GPIR-1a, this can always be achieved by alkylation ofthe natural SH group or groups by reaction with a customary reagent forthiols, such as N-ethylmaleimide or iodoacetic acid or one of itsderivatives, and by methylation of the natural NH₂ groups in accordancewith the reductive methylation process described by MEANS and FEENEY(Biochemistry 7, 2192 (1968)). For example, up to 6 methyl radicals permol can be introduced beforehand into the modified native A chain ofricin. A protein of this type retains all its biological properties andespecially its capacity to inhibit ribosomal protein synthesis ineucaryotic cells.

In the cases of antibodies or antibody fragments and, more generally,all the substances of the first group, as defined previously, which donot possess naturally free SH groups, it will be appropriate to carryout a reductive methylation, for example by the method of MEANS andFEENEY; in this way, it is usually possible to introduce several dozenmethyl radicals per mol of antibody without modifying its capacity toselectively recognize an antigen on the surface of the cells carryingthis antigen.

II--THE PROTEIN P₂

This protein is in all cases the one which carries one or morefunctional groups capable of reacting with the thiols of the protein P₁to form either a disulfide or a thioether bond. These functional groups,which are always introduced artificially into the protein P₂, differaccording to whether it is desired to effect coupling by a disulfidebond or by a thioether bond and are chosen as indicated below.

(1) The Disulfide Bond

In this case, the preparation of the conjugate can be represented by theequation: ##STR6## The protein P₂ substituted by an activated sulfuratom is obtained from the protein P₂ itself or from the correctlyprotected protein P₂ by substitution with a reagent which itself carriesan activated sulfur atom, according to the equation:

    P.sub.2 +L--Y'--R--S--S--X→P.sub.2' --Z'--Y'--R'--S--S--X

in which:

P₂ denotes the protein to be substituted and

L-Y' represents a group permitting the covalent fixation of the reagentto the protein.

The functional group L-Y' is a group capable of bonding covalently withany one of the groups carried by the side chains of the constituentamino acids of the protein to be substituted. Among these groups, thefollowing may be singled out in particular:

(a) The amino end groups of the peptide chains or the amino side groupsof the lysyl radicals contained in the protein. In this case, L-Y' canrepresent especially:

a carboxyl group which can bond to the amino groups of the protein inthe presence of a coupling agent such as a carbodiimide and especially awater-soluble derivarive like1-ethyl-3-dimethylaminopropyl-3-carbodiimide;3-(2-pyridyldisulfanyl)propionic acid activated by the above mentionedcarbodiimide may be used for this purpose.

a carboxylic acid chloride which is capable of reacting directly withthe amino groups to acylate them;

a so-called "activated" ester such as an ortho- or para-nitrophenyl or-dinitrophenyl ester, or alternatively an N-hydroxysuccinimide ester,which can react directly with the amino groups to acylate them, such asthe N-succinimidyl-3-(2-pyridyl-dithio) propionate

an internal anhydride of a dicarboxylic acid, such as, for example,succinic anhydride, which reacts spontaneously with the amine groups tocreate amide bonds; or

an imidoester group: ##STR7## in which R is an alkyl group, which reactswith the amino groups of the protein P₂ according to the equation:##STR8## in which R₃ represents the group --R--S--SX; (b) the phenolgroups of the tyrosyl radicals contained in the protein. In this case,L-Y' can represent especially an imidazol-1-ylcarbonyl group, whichreacts with the phenol groups of the protein according to the equation:##STR9## in which the imidazol-1-yl is L, the CO group is Y' and R₄ isthe group --R--S--S--X.

The radical --S--S--X denotes an activated mixed disulfide capable ofreacting with a free thiol radical. In particular, in this mixeddisulfide, X can denote a pyridin-2-yl or pyridin-4-yl group optionallysubstituted by one or more alkyl, halogen or carboxyl radicals. X canalso denote a phenyl group preferably substituted by one or more nitroor carboxyl groups. Alternatively, X can represent an aIkoxycarbonylgroup such as the methoxycarbonyl group.

The radical R denotes the spacing structure (indicated as E in thegeneral formula II above) capable of carrying the substituents Y' andS--S--X simultaneously. It must be chosen so as not to contain groupscapable of interfering, during the subsequent reactions, with thereactants used and the products synthesized. In particular, the group Rcan be a group --(CH₂)_(n) --, n being between 1 and 10, oralternatively a group: ##STR10## in which R₆ denotes hydrogen or analkyl group having from 1 to 8 carbon atoms and R₅ denotes a substituentwhich is inert towards the reactants t o be used subsequently, such as acarbamate group: ##STR11## in which R₇ denotes a linear or branchedalkyl group having from 1 to 5 carbon atoms, especially the tert.-butylgroup. The reaction of the compound L--Y'--R--S--S--X with the proteinP₂ is carried out in a homogeneous liquid phase, most commonly in wateror a buffer solution. If necessitated by the solubility of thereactants, a water-miscible organic solvent can be added to the reactionmedium at a final concentration which can reach 20% by volume in thecase of a tertiary alcohol, such as tertiary butanol, or 10% by volumein the case of dimethylformamide or tetrahydrofuran.

The reaction is carried out at room temperature for a period of timevarying from a few minutes to a few hours, after which the low molecularweight products, and in particular the excess reactants, can be removedby dialysis or gel filtration. This process usually makes it possible tointroduce between 1 and 15 substituent groups per mol of protein.

When using such compounds, the coupling with the protein P₁ is carriedout by bringing the two proteins together in an aqueous solution havinga pH of between 6 and 8, at a temperature not exceeding 30° C., for aperiod of time varying from 1 hour to 24 hours. The aqueous solutionobtained is dialyzed, if appropriate, to remove the low molecular weightproducts, and the conjugate can then be purified by a variety of knownmethods.

(2) The Thioether Bond

In this case, the preparation of the conjugate consists in reactingP_(1') --(Z--Y--E)_(n) --SH with the protein P₂ into which one or moremaleimide radicals have been introduced beforehand.

The reaction is then represented by the following equation, which isgiven as an example: ##STR12## in which: R₈ represents an aliphatic oraromatic spacing structure containing from 1 to 15 carbon atoms, whichis inert towards the reactants to be used subsequently, and

Z' represents groups which can vary according to the type of functionalgroup substituted on the protein P₂.

Thus, Z'=oxygen in the case of an ester on the phenol of a tyrosylresidue, Z=NH in the case of the coupling of an activated carboxyl groupwith an amino group of the protein, or Z'=NH--CH₂ in the case of thereaction of a chloromethyl ketone with an amino group of the protein.

The protein P₂ substituted by the maleimide group or groups is obtainedfrom the protein P₂ itself, or the correctly protected protein P₂, bysubstitution of suitable groups of the protein with a reagent whichitself carries the maleimide group. Among these suitable groups, thefollowing may be singled out in particular:

(a) The amino end groups of the peptide chains or the amino side groupsof the lysyl residues contained in the protein. In this case, thereagent carrying the maleimide radical can be:

either a reagent of the general formula: ##STR13## in which L--CO--represents: either a carboxyl group, in which case the reaction iscarried out, after activation of the carboxyl group, in the presence ofa coupling agent such as a carbodiimide and especially a water-solublederivative such as 1-ethyl-3-dimethylaminopropyl-3-carbodiimide,

or a so-called "activated" ester such as an ortho- or para-nitrophenylor -dinitrophenyl ester, or alternatively an N-hydroxysuccinimide ester,which reacts directly with the amino groups to acylate them.

The preparation of such reagents is described especially in HelveticaChimica Acta 58, 531-541 (1975). Other reagents in the same class arecommercially available.

or a reagent of the general formula: ##STR14## which is capable ofreacting with the amino groups of the protein P₂ according to theequation: ##STR15## (b) the phenol groups of the tyrosyl radicalscontained in the protein. In this case, the reagent carrying themaleimide radical can be a reagent of the general formula: ##STR16##which reacts with the phenol groups of the protein according to theequation: ##STR17##

The reaction of the maleimide-carrying reagents with the protein P₂ iscarried out in a homogeneous liquid phase, most commonly in water or abuffer solution. If necessitated by the solubility of the reactants, awater-miscible organic solvent can be added t the reaction medium at afinal concentration which can reach 20% by volume in the case of atertiary alcohol, such as tertiary butanol, or 10% by volume in the caseof dimethylformamide or tetrahydrofuran.

The reaction is carried out at room temperature for a period of timevarying from a few minutes to a few hours, after which the low molecularweight products, and in particular the excess reactants, can be removedby dialysis or gel filtration. This process usually makes it possible tointroduce between 1 and 15 substituent groups per mol of protein.

When using such compounds, the coupling with the protein P₁ is carriedout by bringing the two proteins together in an aqueous solution havinga pH of between 6 and 8, at a temperature not exceeding 30° C., for aperiod of time varying from 1 hour to 24 hours. The solution obtained isdialyzed, if appropriate, to remove the low molecular weight products,and the conjugate can then be purified by a variety of known methods.

The compounds of the formula: ##STR18## in which E and G are as definedabove, are prepared by a process which comprises reacting a compound ofthe formula:

    G--E--COOH                                                 VII

in which G and E are as defined above, with the carbonyldiimidazole ofthe formula: ##STR19## in an organic solvent at a temperature of 10° to40° C.

The compounds of the formula Vl are particularly useful as agents forcoupling with the hydroxyls of the tyrosines of the proteins GPIR-1a andP.

According to another feature, the present invention relates to newproducts having the following statistical formula:

    GPIR-1a"--O--E--G                                          IX

in which:

GPIR-1a represents the radical of the protein GPIR-1a or any moleculederived from the said GPIR-1a by artificial modification of any one ofits functional groups, from which one or more phenolic hydroxyl groupsof the tyrosines have been removed;

the oxygen atom is that belonging to the phenolic hydroxyl groupsmissing from the radical GPIR-1a"; and

E and G are as defined above.

Particular preference is given to the compounds of the formuIa IX inwhich E represents a group --(CH₂)_(p) --, in which p is an integer from2 to 7, or a group: ##STR20## and G is a group of the structure--S--S--X, in which X is an activating radical chosen from thepyridin-2-yl and pyridin-4-yl groups which are unsubstituted orsubstituted by one or more halogens or alkyl, carboxyl or alkoxycarbonylradicals, the phenyl group which is unsubstituted or substituted by oneor more halogens or nitro, alkoxy, carboxyl or alkoxycarbonyl groups, oran alkoxycarbonyl group.

The products of the formula IX are prepared by reacting a product of theformula:

    GPIR-1a"--OH

in which GPIR-1a" is as defined above and the hydroxyl group is thephenolic hydroxyl missing from the tyrosines of the radical GPIR-1a",with a compound of the formula VI above, at a temperature of 10° to 40°C., in an aqueous solvent optionally containing a water-miscible organicsolvent such as, for example, an ether solvent like dioxane ortetrahydrofuran.

In the case where GPIR-1a is the prolonged-action A chain of ricin, theproperties of the resulting immunotoxins IT (A-1a) are as follows :

the average degree of coupling, expressed as the number of mol ofmodified A chain per mol of antibody, is usually between 0.5 and 5 andin particular between 1 and 3,

the separation of the IT (A-1a) by polyacrylamide gel electrophoresisresults in a splitting of the product into a series of bandscorresponding to products whose molecular weights differ from that ofthe antibody by successive increments of 30,000 daltons,

the studies performed by cytofluorometry make it possible to show thatthe antibody has not undergone any substantial degradation during theactivation and coupling reactions to which it has been subjected, andthat it is still capable, within the conjugate itself, of recognizingthe antigen against which it is directed, and

the inhibitory activity of the A chain, modified and coupled with anantibody, on protein synthesis, determined in an acellular model in thepresence of 2-mercaptoethanol, is totally retained.

The cytotoxic activity of the immunotoxins with A-1a chain measured in atest for protein synthesis in a cell model on the cells having thetarget antigen, is more than 100 times greater than that measured underthe same conditions on cells not having the target antigen. For example,the immunotoxin (denoted by IT (A-1a) AT15E built up by coupling themodified A chain of ricin, by means of a link containing a disulfidebridge, with a monoclonal antibody (denoted by antibody AT15E) directedagainst the antigen Thy 1.2 present on the surface of certain miceleukemia cells is about 1000 times more cytotoxic towards the positiveThy.1.2 cells than towards the negative Thy 1.2 cells. Moreover, theactivity of IT (A-1a) AT15E is identical to that obtained with ITprepared from the same antibody AT15E and the native cain. Finally,after intravenous administration of IT (A-1a) to rabbits at a dose ofthe order of 0.4 mg/kg of body weight, expressed as A chain, the plasmalevel of IT (A-1a) present in the bloodstream 24 hours after injectionis 50 to 100 times greater than the plasma level of the conventional ITmeasured under the same conditions. Thus, in a typical case involvingrabbits, it is found that the plasma level of IT (A-1a) AT15E in thebloodstream 24 hours after injection is 9% of the product present attime zero, as against 0.08% for the corresponding conventional IT AT15Ewith non-modified A chain, after the same time, i.e. an increase by afactor of the order of 110.

This gives modified immunotoxins which have acquired a new character asregards their pharmacokinetic properties.

More particularly, by appropriate modification of the cytotoxicsub-unit, it has been possible to add to the specific cytotoxicityproperties of immunotoxins, without interfering with them, a newproperty which is just as intrinsic, namely the capacity to show slowplasma elimination kinetics after injection to superior animals orhumans.

Reports have been recently published on works conducted for improvingthe pharmacokinetic properties of ricin and potentially those of theantibodies-ricin conjugates and of the antibodies-A chain of ricinconjugates. These publications are:

European Journal of Biochemistry (1985), 147, 198-206

Biochemica Biophysica Acta (1985), 842, 12-21,

Cancer Drug Delivery (1985), 3, 191-198.

As explained hereinafter, a detailed examination of these publicationshas revealed major differences both regarding methodology and regardingthe results between these works and the works of the Applicant,wherefrom it is obvious that the products according to the presentinvention are very superior.

(A) Regarding Methodology

According to said prior art, the method used for reducing the speed ofelimination in vivo of the ricin and potentially that of theantibody-ricin conjugates and of the antibody-A chain of ricinconjugates, has consisted in modifying the osidic units of the wholericin toxin with a mixture of sodium metaperiodate and sodiumcyanoborohydride at pH 3.5 for short periods of time, the longest beingone hour.

The process developed by the Applicants differs from the above method bythe following points:

(1) the modification takes place exclusively on the molecule of purifiedA chain of ricin;

(2) the reaction pH is much higher (close to neutrality);

(3) the optimum duration of the treatment is much longer (between 4 and20 hours).

It should also be noted that, when the method described in saidpublications is applied directly to the A chain of purified ricin, thelatter is, rapidly and irreversibly, nearly completely denaturated,which makes it improper for any subsequent use. This point has beenexperimentally established by the Applicant. Therefore, the methoddescribed in said publications for the whole ricin, is not directlyapplicable to the molecule of A chain of ricin, so that, the originalprocess for modifying the A chain, discovered by the Applicant is not inany Way anticipated by said publications.

(B) Regarding the Results

(a) Properties of the modified ricin:

The ricin toxin modified according to the method described in saidpublications has the following essential properties:

the biological activity in vitro of the modified ricin namely itscytotoxic power towards culture cells, is very strongly altered by thetreatment, the loss of activity can reach up to 90%.

The overall toxicity in vivo of modified ricin, tested in two species ofanimals (mice and rats) is, on the contrary, increased by a factorvarying between 3 and 4.

It will be noted that these two properties should confer to a conjugate,obtained by coupling an antibody with the ricin modified in that way,properties that are the opposite of what should be expected inimmunotoxins, namely the highest cytotoxic power possible towards targetcells and the lowest possible toxicity.

The hepatic uptake of ricin which is the major phenomenon responsiblefor its elimination from the bloodstream is reduced by a factor 2 whenthe ricin has been modified. The result is an increase in plasmaconcentration of the modified ricin of a factor equal to 2.3 only withrespect to the same concentration when the ricin has not been modified.

It will be further noted that the degree of inhibition of the hepaticuptake of ricin obtained by the chemical modification of its osidicunits is less than that obtained when native ricin is co-administered invivo with an excess of ovalbumin, a glycoprotein which, by its osidicunits with terminal mannose, is a powerful competitor of ricin towardsreceptors of glycoproteins with terminal mannose of the hepatic cells.This indicates that the treatment of ricin such as described in thesepublications is very inadequate to ensure complete destruction of thesugars of ricin which are responsible for the hepatic uptake of toxin.

(b) Biological Properties of A Chain Immunotoxins Issued from ModifiedRicin

The authors of the above-referred publications have built an immunotoxinby using the A chain of ricin purified from modified ricin. The modifiedricin was obtained by treatment of native ricin with sodium periodateand sodium cyanoborohydride at pH 3.5 for 60 minutes. According to theauthors, these conditions are the optimum conditions given the bestcompromise between an increase of the plasma rate of ricin and adecrease of its biological activity (according to these conditions oftreatment, the plasma rate of the so-modified ricin is increased by afactor of 2 to 2.3, whereas its activity is reduced by a factor of 4.7).

The A chain issued from such modified ricin was coupled by means of adisulfide bridge to an antibody directed against certain cancerouscells. The studies on the biological properties of said immunotoxin,reported in said publications reveal a considerably reduced activity.The cytotoxicity induced by this conjugate towards the target cells isless by a factor of 3 to 4 than that of the same conjugate built withthe A chain of native ricin, this implying that the treatment of thericin such as described by said authors, which is detrimental to thebiological activity of ricin, is also detrimental to the immunotoxinsbuilt with the A chain issued from said modified ricin.

A fact to be remembered is that, on the contrary, the immunotoxins withA-1a chain prepared according to the process of the present application,exhibit cytotoxic activities towards target cells, which are identicalto that obtained with the same homolog immunotoxins built with the Achain of native ricin.

(c) Pharmacokinetic Properties of the A Chain Issued from Modified Ricinand Pharmacokinetic Properties of the Corresponding Immunotoxins

From the results reported hereinabove, the authors of said publicationsexpect that the immunotoxins prepared with the A chain issued from thericin modified according to their method, should have improvedpharmacokinetic properties, namely a slower speed of elimination fromthe blood compartment, thereby increasing their biological properties.However, no experiment results have really proved this essential point.Moreover, such conclusion cannot even be drawn from the publishedinformation for the following reasons:

The only results of pharmacokinetics which are given ate those obtainedexperimentally with the whole toxins (ricin and modified ricin) and notwith the corresponding A chains. Yet, the ricin toxin contains anoligosaccharidic unit on the B chain. These osidic units, being all withterminal mannose, are also susceptible to be recognized by thenon-parenchymal cells carrying receptors capable of recognizing saidoses. In practice, it is not known whether the osidic units involved inthe ricin elimination process are those carried by the A chains or the Bchains or both. It is therefore impossible to know whether the osidicunits responsible for the rapid elimination of the A chain, is explainedby the Applicant, arc the same as those which are also involved in theelimination of ricin.

Consequently, the partial inhibiting of the hepatic uptake of the ricinmodified by the process described in the above-cited publications, whichproves that the osidic units involved in said process applied to thewhole ricin, have been partly modified, does not in any way indicatethat the modification of the osidic units of the A chain obtained whenworking on the whole ricin, is appropriate to ensure an inhibition ofthe hepatic uptake of the isolated A chain, hence a slow eliminationthereof and of the corresponding immunotoxins.

The Applicant has then undertaken certain works to determine thepharmacokinetic properties of the A chain isolated from ricin modifiedaccording to the method described in the above-cited publications and ofthe corresponding immuno-toxins. The experimental procedures followedfor (1) the modification of ricin, (2) the isolation of the A chain, (3)the coupling of said A chain with the antibody, are strictly identicalto those described in said publications, and in publications cited inreference therein.

The results obtained with the A chain issued from ricin modifiedaccording to the process described in said publications are compiled inTable I, which also gives, for comparative purposes, the resultsobtained with the native A chain and with the A-1a chain preparedaccording to the present invention.

                  TABLE I                                                         ______________________________________                                                               A chain                                                                       issued                                                                 Native from modi-                                                                              A-la                                                         A chain                                                                              fied ricin                                                                              chain                                        ______________________________________                                        Inhibition of protein                                                                           10-.sup.10 M                                                                           10-.sup.9 M                                                                             1.2                                      synthesis in acellular               10-.sup.10 M                             model (CI 50)                                                                 Free thiol per mole of A chain                                                                  0.9      0.77      0.79                                     Molecular weight ± 3,000                                                                     30,000   30,000    30,000                                   Relative plasma concen-                                                                         0.015    0.04      5                                        tration (%) 24 h after                                                        the injection                                                                 ______________________________________                                    

Thus, said results show that the A chain of modified ricin exhibitsproperties that are identical to those of the A-1a chain as regards thenumber of free thiols per mole of A chain and the molecular weight. Onthe contrary, these two products differ considerably as far as theirbiological properties are concerned:

(1) the intrinsic biological activity of the A chain, which is its powerto inhibit the protein synthesis, is reduced by a factor 10 for the Achain issued from modified ricin, whereas it is not altered (or by anunsignificant factor) for the A-1a chain.

(2) The difference as regards the pharmacokinetic properties is evenmore spectacular. The plasma concentration measured 24 h after theinjection is 125 times greater for the A-1a chain than for the A chainissued from the modified ricin, of which the capacity to remain in theblood stream is only improved by a factor equal to 2.6 with respect tothe native A chain.

The pharmacokinetic results and he results of biological activity of theimmunotoxins built with the A chain issued from modified ricin arecompiled in Table II which also gives, for comparative purposes, theresults obtained with the immunotoxins built with the native A chain andwith the A-1a chain prepared according to the invention.

                  TABLE II                                                        ______________________________________                                                             Immunotoxin                                                           Immuno- with A chain                                                                             Immuno-                                                    toxin   issued from                                                                              toxin                                                      with native                                                                           modified ri-                                                                             with A-la                                                  A chain cin        chain                                         ______________________________________                                        Concentration necessary                                                                      2,10-.sup.10 M                                                                          >10-.sup.9 M                                                                             2,10-.sup.10 M                            for inhibiting by 50%                                                         the synthesis of the                                                          proteins from the                                                             target cells (IC.sub.50)                                                      Relative plasma concentra-                                                                   0.08      0.6        9                                         tion (%) 24 h after                                                           the injection                                                                 ______________________________________                                    

These results indicate that:

(1) The capacity of A chain immunotoxins issued from modified ricin toremain in the bloodstream in vivo is considerably less than thatrecorded with the A-1a chain immunotoxins. 24 hours after the injection,the difference corresponds to a factor equal to 15.

(2) The cytotoxic activity towards the target cells, of the A chainimmunotoxins issued from modified ricin, is at least 20 times less thanthat of the native A chain or A-1a chain immunotoxins which exhibitidentical cytotoxic activities. These results show the very greatsuperiority of the immunotoxins prepared according to the invention overthose prepared from the intermediates described in the literature.

This comparative test carried out between the works described in theliterature and those described in the present application, thus confirmsthe completely unexpected nature of the results obtained by theApplicant and emphasizes the high degree of improvement brought by thenew molecules of A-1a chain and by the new molecules of immunotoxins ofA-1a chain.

The following examples are given non-restrictively to illustrate theinvention.

EXAMPLE 1

This example demonstrates the slow elimination of the A chain of ricinmodified with sodium periodate and by simultaneous reduction reactionwith sodium cyanoborohydride after intravenous injection into theanimal.

(A) Modification of the A Chain of Ricin by Simultaneous Action ofSodium Periodate and Sodium Cyanoborohydride

(1) Blocking of the natural SH with DTNB The A chain of ricin wasprepared and purified in the manner indicated in U.S. Pat. No.4,340,535. 20 equivalents of a solution of2,2'-dinitro-5,5'-dithio-dibenzoic acid (DTNB), under the form of asolution of DTNB in a 125 mM phosphate buffer (this solution is broughtto pH 7 with sodium hydroxide), are added to 20 ml of a solution of Achain of ricin containing 0.81 thiol group per mole of A chain at theconcentration of 6 mg/ml, in a 125 mM phosphate buffer, pH 7. Incubationis left to proceed for 30 minutes at 20° C. The solution is thendialyzed against PBS buffer (a buffer 20 mM in respect of phosphate and150 mM in respect of NaCl, pH 7). After centrifuging at 10,000 x g for30 minutes, 107 mg of A chain blocked on the thiol group, are obtainedas a solution containing 5.5 mg/ml.

(2) Periodate Oxidation and Reduction by Sodium Cyanoborohydride of AChain Blocked on the Thiol Group

The whole of this procedure is carried out at 4 ° C. ml of acetatebuffer 0.2M, pH 6.5 are added to 107 g of A chain blocked on the thiolgroup contained in 19.5 ml, and this solution is brought to a pH of 6.5with an acetate buffer 0.2M of pH 3.5. A solution of sodiumcyanoborohydride at 160 mM is prepared in the acetate buffer of pH 6.5.A solution of sodium periodate at 80 mM is prepared in the acetatebuffer of pH 6.5, said solution being kept away from the light. Then, 19ml of the sodium periodate solution are mixed in the dark with 19 ml ofsodium cyanoborohydride solution. After 10 minutes, still in the dark,38 ml of the solution of A chain blocked on the thiol group are added tothe mixture of sodium periodate and sodium cyanoborohydride, andincubation is allowed to proceed for 17 hours at 4° C. in the dark. Thereaction is stopped by addition of 2.7 ml of a solution of glycerol at20% (v/v) in the acetate buffer 0.2M of pH 6.5. Incubation is allowed tocontinue for 20 hours at 4° C. and the solution is extensively dialysedat 4° C., for 48 hours against an ammonium bicarbonate buffer 50 mM, pH7.8.

After centrifugation at 10,000 x g for 30 minutes, 74 ml of solution at0.82 mg/ml of A-1a chain blocked on the thiol function and modified onits osidic residues by oxidation and reduction is obtained.

(3) Unblocking of the Thiol Groups

74 ml of 0.82 mg/ml solution of A-1a chain blocked and modified on itsosidic units are returned to 16.8 ml by concentration, then 0.406 ml of2-mercapto-ethanol at 50% are added. Incubation is allowed to proceedfor 1 h at 20° C. Then the solution is dialyzed against PBS buffer at 4°C. And 45 mg of modified A-1a chain are obtained of concentration 2.87mg/ml.

Using the DTNB technique (Methods in Enzymology, 1972, 25, 457 (AcademicPress)), it is determined that the modified A chain obtained has 0.79free thiol group per mol. The molecular weight of the modified A chainis 30,000±3,000, determined by polyacrylamide gradient electrophoresisin the presence of sodium dodecyl-sulfate.

The previously obtained preparation of A-1a chain was studied for itsenzymatic activities in the inhibition of protein synthesis and for itspharmacokinetic properties.

B--Enzymatic Activity of the Prolonged-Action A Chain, Measured on anAcellular Model

The fundamental biological property of the A chain of ricin is toinhibit protein synthesis in cells by degradation of the ribosomalsub-unit 60S.

The in vitro protocol involves the use of appropriately complemented,subcellular fractions of rat liver capable of incorporating ¹⁴C-phenylalanine in the presence of an artificial messenger RNA:polyuridylic acid.

The procedure employed for preparing the subcellular fractions andmeasuring the incorporation of ¹⁴ C-phenylalanine is an adaptation ofthe method described in Biochemica Biophysica Acta 1973, 312, 608-615,using both a microsomal fraction and a cytosol fraction of the rathepatocytes. The sample containing the A chain is introduced in the formof a solution appropriately diluted in a 50 mM Tris HC1 buffer of pH 7.6containing 0.2% of 2-mercaptoethanol and 15 micrograms/ml of bovineserum albumin.

The count data are used to calculate, relative to a control mediumwithout inhibitor, the percentage inhibition of the incorporation of ¹⁴C-phenylalanine into the proteins for each reaction medium containing Achain of ricin.

With the curves obtained, it is possible to calculate the IC₅₀ orconcentration of A chain (native or modified) which inhibits by 50% theincorporation of the radiolabeled precursor in the proteins. An IC₅₀ isthus observed which is equal to 1.2.10⁻¹⁰ mole/l for the A-1a chainaccording to the invention. The IC₅₀ of the control A chain in theexperiment is 10⁻¹⁰ mole/l: considering the precision of themeasurements, the modification does not entail any significant loss ofactivity of the A chain.

C--Pharmacokinetic Properties of the Prolonged-Action A Chain Modifiedon its Polysaccharide Units

The A chain (native or modified) is administered to rabbits by means ofa single injection into a vein in the ear. The quantity of A chaininjected corresponds to 0.415 mg/kg. Blood samples are taken atintervals on heparin. The plasmas are analyzed with the aid of aradioimmunometric test designated below by the abbreviation RIM-1.

This technique has the advantage of determining the A chain withoutmodifying it. This determination is carried out in microtitration plates(for example: "NUNC-TSP screening system" from Poly Labo Block France),the lid of which carries hyperabsorbent spikes which dip into the wellsin the base. These spikes constitute the solid phases. Sheep antibodiesdirected against the A chain of ricin (designated below by theabbreviation Ac1), purified by affinity chromatography, are absorbed onthe solid phases. For this purpose, 200 microliters of a solution of Ac1containing 10 micrograms/ml in PBS phosphate buffer are divided up intothe wells. The spikes are brought into contact firstly with the solutionof Ac1 for 24 h at 4° C. and then with fetal calf serum for 3 h at 20°C. in order to saturate all the fixation sites. The saturatedimmunoabsorbent is then brought into contact for 3 h at 20° C. with theplasma samples to be determined at different dilutions, or withsolutions of A chain of known concentrations in order to establish thecalibration curve. After washing with a PBS buffer, the immunoabsorbentis brought into contact for 2 h at 20° C. with the sheep antibodiesdirected against the A chain of ricin, which have been purified byaffinity chromatography and radiolabeled (designated below by theabbreviation Ac2). The radiolabeling of the Ac2 is effected with iodine125 in the presence of chloramine 1 by the method of Greenwood andHunter Biochem.J., 1963, 89, 114); the specific activity of theradiolabeled Ac2 antibodies is 5 to 10 microcuries/microgram. 10⁶ cpm ofradiolabeled Ac2 antibodies are introduced as 200 microliters into a pBSbuffer containing 0.1% of bovine serum albumin. After washing in pBSbuffer, the spikes are detached and the quantity of bound Ac2 ismeasured by counting the radioactivity. The concentration of A chain inthe samples to be determined is measured by reference to the calibrationcurve established by introducing the A chain at different knownconcentrations. When prolonged-action A chain is injected into theanimal, this same prolonged-action A chain is used to establish thecorresponding calibration curve.

The values of the concentration of A chain (native or modified) in theblood plasma measured by this technique are reproducible and reliable.The detection threshold is 1 nanogram/ml. A study of the reproducibilitywithin and between experiments gives coefficients of variation of lessthan 10% for concentration values within the range from 1 to 200nanograms/ml.

The results of these experiments are represented in the form of curvesin which the time, expressed in hours, is plotted on the abscissa andthe plasma concentration of the product measured, recorded in per centof the theoretical plasma concentration at time zero, is plotted on alogarithmic scale on the ordinate. This value, called the "relativeplasma concentration" (RPC), is calculated using the followingexpression: ##EQU1##

The plasma volume is considered to be equal to 36 ml/kg of the animal'sbody weight.

FIG. 1 shows the plasma elimination curve, as a function of time, forthe native A chain of ricin and for the modified A-1a chain injectedintravenously. This curve (curve 1) has two phases: in the first phase,the product disappears very rapidly from the bloodstream since only 0.1%of the dose administered remains in the plasma three hours afterinjection. In the second phase, the decrease is slower.

When the A chain has been modified on its osidic units (chain A-1a,curve 2), the elimination profile is profoundly modified: the firstelimination phase--which is responsible for the disappearance of themajority of the product--is practically suppressed, which leads to aconsiderable increase in the plasma levels of A chain. Twenty four hoursafter injection, the concentration of the oxidized A chain is 330 timesgreater than in the case of the unmodified A chain (curve 2).

These results therefore show that the oxidation reaction with the sodiumperiodate and the reduction of the aldehyde groups which have appeared,with formation of primary alcohol, by the action of the sodiumcyanoborohydride, have modified the sugars implicated in the recognitionprocess responsible for the elimination of the A chain to the point ofpreventing said recognition without the biological activitycharacteristic of the A chain being altered.

EXAMPLE 2

This example demonstrates the importance of the duration of theoxidative treatment on the pharmacokinetic properties of the oxidizedand reduced A chain.

Five preparations of A-1a chain are made using the procedure indicatedin Example 1, except for the duration of the treatment by the sodiumperiodate plus sodium cyanoborohydride treatment. The treatment timesare as follows: zero (reaction stopped immediately with glycerol), 30minutes, 1 hour, 2 hours, 4 hours and 16 hours.

These various preparations are injected into rabbits and the relativeplasma concentration of the A-1a chain is measured after 24 hours by thesame procedure as in Example 1.

The results are shown in FIG. 2, on which the RPC after 24 hours isgiven in ordinate and the duration of the periodate-cyanoborohydridetreatment is given in abscissae.

These results indicate that:

(1) the increase in the plasma level of the A chain is indeed due tooxidation and reduction reaction because, when the reaction is stoppedimmediately, the plasma concentration of A chain is identical to thatobtained with the native A chain,

(2) it is necessary for the duration of this reaction to be relativelylong in order to obtain optimum effects.

EXAMPLE 3

The immunotoxin (abbreviated IT) obtained by reaction between anantibody directed against mice T cells (antibody directed againstantigen Thy 1.2) substituted by activated disulfide groups and A-1achain of ricin:

(a) Antibody directed against mice T cells or AT15E antibody:

This antibody was obtained according to the method described in Journalof Immunology. 1979, 122, 2491-2498.

(b) A-1a chain of ricin:

The A-1a chain of ricin which was used was prepared as indicated inExample 1.

(c) Activated Antibody directed against mice T cells:

4.25 mg of N-succinimidyl-3-(2-pyridyl-dithio)propionate in ethanol at95% under a volume of 0.5 ml, are added to 10 ml of a 5.83 mg/mlsolution of antibody in a borate buffer 0.1M pH8.3. The mixture isstirred for 30 minutes at 20° C. After dialysis against a 125 mMphosphate buffer of pH 7, the protein solution is centrifuged at10,000×g for 30 minutes at 4° C., and 57.3 mg of activated antibody arethus obtained at a concentration of 4.66 mg/ml. By spectrophotometricdosage at 343 nm of 2-pyridinethione liberated by exchange with2-mercaptoethanol, it is found that an antibody is obtained whichcarries 3.75 activated mixed disulfide groups per mole of antibody.

(d) Preparation of the immunotoxin having the prolonged-action A-1achain of ricin.

8.9 ml of A-1a chain at 2.87 mg/ml obtained as indicated in Example 1are added to 6.5 ml of the activated antibody solution obtainedhereinabove (concentration 4.66 mg/ml, i.e. 30.3 mg of activatedantibodies), and incubation is left to proceed for 20 hours at 25° C.The solution is centrifugated, then purified by filtration on a gel (AcA44 gel) with measurement of the optical density of the effluent at 280nm. Regrouping of the fractions containing both the antibody and themodified A chain leads to 32 ml of immunotoxin solution at 0.4 mg/ml,i.e. 12.8 mg. This solution contains 0.107 mg of modified A-1a chaincoupled to the antibody per ml. The average coupling rate of thispreparation is therefore 1.8 mole of A-1a chain per mole of antibody.

The immunotoxin with A-1a chain of ricin obtained as indicated above wasstudied for its pharmacokinetic properties and its specific cytotoxicproperties towards the target cells.

EXAMPLE 4

This example shows how the slow plasma elimination property is acquiredby the prolonged-action immunotoxins with A chain of ricin, abbreviatedto IT (A-1a).

(A) Procedure

The conjugate prepared according to the method described in Example 3 isadministered to the rabbit by a single injection in a vein of the ear.The injected quantity corresponds to 0.415 mg/kg expressed in A chain.Blood samples are taken at intervals on heparin. The plasmas areanalyzed with the aid of radioimmunometric tests with two siteshereinafter designated by the abbreviation RIM-3.

This assay is carried out by the same technique as that used for thetest RIM-1 (described in Example 1) except that the solution Ac2 is herea solution of goat antibodies directed against mouse IgG, purified byaffinity chromatography and radiolabeled as described for the RIM-1technique (described in Example 1). The concentration of modifiedimmunotoxin in the samples is measured by reference to a calibrationcurve established by introducing the modified immunotoxin at differentknown concentrations. The assay RIM-3 has the same reliability andreproducibility characteristics as described for the RIM-1 technique.

By way of comparison, a control study is carried out under the sameconditions with the conjugate called IT-AT15E, which is obtained by thereaction of the same antibody AT15E, substituted by activated disulfidegroups, with the native A chain of ricin. The preparation of thisconjugate is carried out by the same method as described in Example 3.The results of these pharmacokinetic experiments are represented in thesame way as for the uncoupled A chain of ricin in Example 1.

(B) Results

FIG. 3 shows the plasma elimination curves, as a function of time, forconventional IT AT15E (curve 1) and IT (A-1a) AT15E (curve 2), injectedintravenously. 24 hours after injection, the concentration of activeimmunotoxin is 110 times greater for IT (A-1a) AT15E than for theconventional ITAT15E. This fact demonstrates that the newpharmacokinetic properties of the oxidized A chain are retained aftercoupling with an antibody.

EXAMPLE 5

This example demonstrates the retention of the specific cytotoxicityproperties of IT (A-1a) AT15E towards the positive target cells Thy 1.2.

The fundamental biological property of the A chain of ricin is toinhibit protein synthesis in cells by degradation of the ribosomalsub-unit 60S. The technique uses a cell model in which the effect of thesubstances studied on the incorporation of ¹⁴ C-leucine into cancerouscells in culture is measured.

The cells used belong to the cell line T2 derived from a T leukemiawhich carries the antigen Thy 1.2. The cells are incubated in thepresence of the substance to be studied, and then, when incubation hasended, the degree of incorporation of ¹⁴ C-leucine by the cells treatedin this way is measured. The experiment is carried out in the presenceor in the absence of ammonium chloride at the final concentration, of 10mM, known to increase the cytotoxic activity of the immunotoxin.

This measurement is made by a technique adapted from the one describedin Journal of Biological Chemistry 1974, 249(11), 3557-3562, using thetracer ¹⁴ C-leucine to determine the degree of protein synthesis. Theradioactivity incorporated is determined here on the whole cellsisolated by filtration.

On the basis of these determinations, it is possible to draw thedose/effect curves, plotting, on the abscissa, the molar concentrationof A chain in the substances studied, and, on the ordinate, theincorporation of ¹⁴ C-leucine expressed as a percentage of theincorporation by control cells in the absence of any substance affectingprotein synthesis.

It is thus possible to determine, for each substance studied theconcentration which causes a 50% inhibition of the incorporation of ¹⁴C-leucine, or "50% inhibitory concentration" IC₅₀).

Table II hereinafter represents the values of IC₅₀ obtained in the sameexperiment with IT (A-1a) AT15E and IT AT15E with or without ammoniumchloride on the one hand, and with the native A chain and the uncoupledA-1a chain on the other hand.

It is found that the IT (A-1a) AT15E has a very strong cytotoxicactivity, identical to that obtained with the corresponding immunotoxinwith native A chain and which is about 1,000 times greater than that ofthe A-1a chain, measured in the same conditions.

It is also found that the IT (A-1a) AT15E fully retains its capacity tobe potentiated by ammonium chloride.

                  TABLE III                                                       ______________________________________                                        Products         Inhibiting concentration 50                                  ______________________________________                                        IT (A-la) AT15E  2.10-.sup.10 M                                               IT (A-la) AT15E  3.10-.sup.11 M                                               +10 mM NH4Cl                                                                  IT AT15E         2.10-.sup.10 M                                               IT AT15E         3.10-.sup.11 M                                               +10 mM NH4Cl                                                                  Native A chain   3.10-.sup.7 M                                                A-la chain       2.10-.sup.7 M                                                ______________________________________                                    

EXAMPLE 6

This examples shows, after intravenous injection into the animal,

(1) the rapid elimination of native gelonine and

(2) the slow elimination of gelonine modified by oxidation reaction withsodium periodate and by simultaneous reduction reaction with sodiumcyanoborohydride.

(A) Modification of Gelonine by the Simultaneous Action of SodiumPeriodate and Sodium Cyanoborohydride

The gelonine was prepared and purified from Gelonium multiflorum by themethod which has been described (J. Biol. Chem. (1980) 255, 6947-6953).The oxidation reaction is carried out under the same conditions as thosedescribed for the A chain of ricin in Example 1, except that the step inwhich the thiols are blocked with DTNB is omitted.

In fact, as the coupling of gelonine with the antibody is not generallyperformed using natural thiol groups of the gelonine, the thiol groupswill be introduced artificially, after the oxidation step, by thetechnique described in Cancer Res., 1984, 44, 129-133. 1 ml of a 0.2Macetate buffer, pH 6.5 is added to 1 ml of a solution containing 5 mg/mlof gelonine in PBS buffer, and the pH is brought to 6.5 with 0.2Macetate buffer pH 3.5. A 160 mM sodium cyanoborohydride solution inacetate buffer pH 6.5 is prepared. A 80 mM sodium periodate solution inan acetate buffer pH 0.5 is prepared and this solution is keeped in thedark. Then, 1 ml of the sodium periodate solution is mixed in the darkwith 1 ml of the sodium cyanoborohydride solution. After 10 minutes, 2ml of the gelonine solution is added in the dark to the mixture ofsodium periodate/sodium cyanoborohydride. Incubation is left to proceedfor 17 hours at 4° C. in the dark. The reaction is stopped by theaddition of 142 microliters of 20% (v/v) glycerol solution in 0.2Macetate buffer pH 6.5. Incubation is left to proceed for 20 hours at 4°C., then the reaction medium is dialyzed at 4° C. for 48 hours againstan ammonium bicarbonate buffer 50 mM pH 7.8. After centrifugation at10,000×g for 30 minutes, this gives 2.8 mg of oxidized gelonine at aconcentration of 0.7 mg/ml.

Like the A chain of rioin, the fundamental property of gelonine is toinhibit protein synthesis in eucaryotic cells by degradation of theriboscmal sub-unit 60S (Biochem. J., 1982, 207, 505-509). In the case ofgelonine too, the modification does not cause any significant loss ofactivity.

(B) Pharmaookinetic Properties of Prolonged-Action Gelonine

Native gelonine or gelonine modified by the procedures explained aboveis administered to rabbits by a single injection into a vein in the ear.The quantity of gelonine injected is between 0.3 and 0.4 mg/kg. Bloodsamples are taken at intervals on heparin. The plasmas are analyzed withthe aid of a radioimmunometric test designated beIow by the abbreviationRIM-2.

This test is performed by the same technique as used for the test RIM-1,except that the solution Ac1 here is a solution of anti gelonine rabbitantibodies purified by affinity chromatography, the Ac2 antibodies beingthe same antibodies radioIabeIed. The radiolabeling procedure isidentical to that described for the technique RIM-1. The concentrationof native gelonine or modified gelonine in the samples to be determinedis measured by reference to a calibration curve established byintroducing native or modified gelonine at different knownconcentrations. The test RIM-2 has the same reliability andreproducibility characteristics as described for the technique RIM-1.

The plasma elimination curves, as a function of time, for nativegelonine and modified gelonine, injected intravenously, show that thenative gelonine, like the native A chain of ricin, disappears veryrapidly from the bloodstream since the gelonine present in thebloodstream disappears in 24 hours. When the gelonine has been modifiedon its polysaccharide units, the elimination profile is profoundlymodified 24 hours after injection, the concentration of the modifiedgelonine is 250 times greater than that of the native gelonine.

Thus, as for the A chain of ricin, these results prove that the sodiumperiodate oxidation and the reduction of aldehyde groups appeared withthe formation of primary alcohol by the action of sodiumcyanoborohydride, modified the sugars involved in the recognitionprocess responsible for the elimination of the gelonine, to the point ofpreventing this recognition.

These modified immunotoxins can be used for the treatment of cancerousor non-cancerous diseases where the target cells would be recognized bythe antibody used for preparing the immunotoxin. The optimumadministration conditions, and the treatment time will have to bedetermined in each case according to the subject and to the nature ofthe disease to be treated. The new drugs according to the invention arepresented in a form suitable for the administration by injection andpreferably intravenous injection.

We claim:
 1. A modified glycoprotein which inactivates ribosomes andhaving the ribosome-inhibiting activity of the corresponding nativeglycoprotein which inactivates ribosomes, and an in vivoprolonged-action with respect to the corresponding native glycoproteinwhich inactivates ribosomes, wherein said modified glycoprotein whichinactivates ribosomes is obtained by treatment of a glycoprotein whichinactivates ribosomes having a molecular weight from about 20,000 to30,000 jointly with an aqueous solution of a periodate and an aqueoussolution of cyanoborohydride at pH 5 to 7 for a period of 0.2 to 24hours.
 2. A modified glycoprotein which inactivates ribosomes as claimedin claim 1, wherein the treatment is carried out in the dark at atemperature of from 0° to 15° C.
 3. A process for the preparation of amodified glycoprotein which inactivates ribosomes as claimed in claim 1,wherein a glycoprotein which inhibits ribosomes and has a molecularweight of from about 20,000 to about 30,000 is treated jointly with anaqueous solution of a periodate and an aqueous solution of acyanoborohydride at a pH of from 5 to 7, at a temperature of 0° to 15°C., in the dark and for a period of 0.2 to 24 hours.
 4. Modifiedglycoprotein which inactivates ribosomes as claimed in claim 1, whereinat least one of the thiol groups of the GPIR is protected during thetreatment.
 5. Modified glycoprotein which inactivates ribosomes asclaimed in claim 2, wherein the reaction solution contains between 1 and10 mg/ml of reactive A chain, 10 to 50 mM alkaline periodate and 10 to200 mM sodium cyanoborohydride.
 6. Process as claimed in claim 3,wherein the reaction solution contains between 1 and 10 mg/ml ofreactive A chain, 10 to 50 mM alkaline periodate and 10 to 200 mM sodiumcyanoborohydride.
 7. Process as claimed in claim 6, wherein theglycoprotein which inactivates ribosomes is treated beforehand with aconventional reagent protecting the protecting groups, and said groupsSH are released after the treatment by the IO₄ ⁻ ions and thecyanoborohydride.
 8. Process as claimed in claim 7, wherein the reagentprotecting the groups SH is selected from the2,2'-dinitro-5,5'-dithio-dibenzoic acid and3-(2-pyridyldisulfanyl)propionic acid, the deprotection of the SH groupsbeing achieved by the action of 2-mercaptoethanol.
 9. Immunotoxin havinga prolonged-action in vivo, resulting from the coupling of an antibodyor antibody fragment with a modified glycoprotein which inactivatesribosomes according to claim
 1. 10. Immunotoxin as claimed in claim 9,wherein the coupling between the antibody or antibody fragment and themodified GPIR is carried out by means of a disulfide bridge. 11.Immunotoxin as claimed in claim 10, wherein the coupling is carried outwith a heterobifunctional reagent selected from theN-succinimidyl-3-(2-pyridyldithio)propionate or the3-(2-pyridyldisulfanyl) propionic acid activated by1-ethyl-3-(3-dimethylaminopropyl) carbodiimide.
 12. Anti-cancerouspharmaceutical composition containing as active principle, animmunotoxin as claimed in claim
 9. 13. An immunotoxin having aprolonged-action in vivo, resulting from the coupling of an antibodyfragment with a modified glycoprotein which inactivates ribosomesaccording to claim
 4. 14. An immunotoxin having a prolonged-action invivo, resulting from the coupling of an antibody fragment with amodified glycoprotein which inactivates ribosomes according to claim 2.15. An immunotoxin having a prolonged-action in vivo, resulting from thecoupling of an antibody or antibody fragment with a modifiedglycoprotein which inactivates ribosomes according to claim
 5. 16. Animmunotoxin as claimed in claim 13 where the coupling is carried out bymeans of a dissulfide bridge.
 17. An immunotoxin as claimed in claim 14where the coupling is carried out by means of a disulfide bridge.
 18. Animmunotoxin as claimed in claim 15 where the coupling is carried out bymeans of a disulfide bridge.
 19. A pharmaceutical composition containingas active principal, an immunotoxin as claimed in claim
 13. 20. Apharmaceutical composition containing as active principal, animmunotoxin as claimed in claim
 14. 21. A pharmaceutical compositioncontaining as active principal, an immunotoxin as claimed in claim 15.22. A modfified glycoprotein as claimed in claim 1 wherein the modifiedglycoproteins is the A chain of ricin.